{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:41:31Z","timestamp":1788871291345,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2012.09.012","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:31:03Z","timestamp":1350952263000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid"],"prefix":"10.1016","volume":"22","author":[{"given":"Jason","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Nickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Biskupiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed B.","family":"Barney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Namjoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2012.09.012_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3816\/SCT.2007.n.003","article-title":"Treatment of bone metastases and bone pain with bisphosphonates","volume":"4","author":"Lipton","year":"2007","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.breast.2012.09.012_bib2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"20","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2012.09.012_bib3","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.09.012_bib4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.09.012_bib5","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.breast.2012.09.012_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.09.012_bib7","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.09.012_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","article-title":"Breast cancer. Clinical practice guidelines in oncology","volume":"7","author":"Carlson","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"Suppl. 3","key":"10.1016\/j.breast.2012.09.012_bib9","first-page":"S1","article-title":"NCCN Task Force report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2012.09.012_bib10","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.breast.2012.09.012_bib11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.breast.2012.09.012_bib12","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2012.09.012_bib13","unstructured":"Amgen Inc. Thousand Oaks, CA: November 2010 [accessed at http:\/\/www.xgeva.com\/]."},{"key":"10.1016\/j.breast.2012.09.012_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2407-5-89","article-title":"Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer","volume":"5","author":"Liauw","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2012.09.012_bib15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3109\/07357900902783203","article-title":"Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer","volume":"27","author":"Crawford","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.breast.2012.09.012_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","article-title":"Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis","volume":"11","author":"Hatoum","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2012.09.012_bib17","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.09.012_bib18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2012.09.012_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","article-title":"Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates","volume":"28","author":"King","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.breast.2012.09.012_bib20","unstructured":"Data Resource Center Homepage. University of Utah, Salt Lake City, UT: July 2011 [accessed at http:\/\/uuhsc.utah.edu\/drc\/]."},{"key":"10.1016\/j.breast.2012.09.012_bib21","unstructured":"Huntsman Cancer Institute Homepage. University of Utah, Salt Lake City, UT [accessed 18.02.11] [accessed at http:\/\/www.huntsmancancer.org\/]."},{"key":"10.1016\/j.breast.2012.09.012_bib22","unstructured":"Utah Resource for Genetic and Epidemiological (RGE) Research Homepage. University of Utah, Salt Lake City, UT [accessed 24.11.10] [accessed at http:\/\/www.research.utah.edu\/rge\/]."},{"key":"10.1016\/j.breast.2012.09.012_bib23","series-title":"Zometa prescribing information","year":"2009"},{"key":"10.1016\/j.breast.2012.09.012_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.breast.2012.09.012_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.breast.2012.09.012_bib26","first-page":"693","article-title":"Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer","volume":"16","author":"Barlev","year":"2010","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.breast.2012.09.012_bib27","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.breast.2012.09.012_bib28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ejso.2006.06.001","article-title":"Patterns of breast cancer relapse","volume":"32","author":"Elder","year":"2006","journal-title":"Eur J Surg Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612001981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612001981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:37Z","timestamp":1760776237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977612001981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0960977612001981"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2012.09.012","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2012.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}